Page 2 - Global Vaccine Business Unit News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Takeda, Biological E tie up for dengue vaccine production - The Hindu BusinessLine

Takeda, Biological E tie up for dengue vaccine production - The Hindu BusinessLine
thehindubusinessline.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thehindubusinessline.com Daily Mail and Mail on Sunday newspapers.

Gary dubinBiologika gmbDengue tetravalent vaccineGlobal vaccine business unitBiologicale limited

Dengue vaccine India: Takeda, Biological E enter manufacturing pact to produce 50 million doses of Dengue vaccine

Japanese drug giant Takeda has partnered with Indian vaccine maker Biological E (BE) to manufacture its Dengue vaccine. BE will increase its manufacturing capacity to up to 50 million doses a year, supporting Takeda s goal to produce 100 million doses annually by 2030. The collaboration leverages Takeda s existing facility in Germany and its partnership with IDT Biologika GmbH.

United kingdomMahima datlaBiologika gmbGary dubinSouth east asiaNational immunization programsNational immunizationGlobal vaccine business unitWestern pacificDengue vaccine indiaBiological eDengue vaccineManufacturing capacity

Takeda Accelerates Access to its Dengue Vaccine Through Make in India Manufacturing Partnership with Biological E

Takeda Accelerates Access to its Dengue Vaccine Through Make in India Manufacturing Partnership with Biological E
bignewsnetwork.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bignewsnetwork.com Daily Mail and Mail on Sunday newspapers.

Andhra pradeshUnited statesUnited kingdomGary dubinDuddilla sridhar babuAnumula revanth reddySouth east asiaDion warrenStrategic advisory group of expertsTakeda pharmaceutical company limitedEuropean unionWorld health organizationPharmceutical technologyLancet global healthEuropean medicines agencySustainable development goals

Biological E to make 50 million doses of Takeda s dengue vaccine QDENGA

India Business News: Takeda and Biological E Limited have partnered to manufacture up to 50 million doses per year of the dengue vaccine QDENGA, with the goal of deliverin

Andhra pradeshMahima datlaGary dubinBe limitedBiologicale limitedGlobal vaccine business unitDengue tetravalent vaccineBusiness newsDengue vaccineBiological e

Business News | Takeda Accelerates Access to Its Dengue Vaccine Through Make in India Manufacturing Partnership with Biological E

Get latest articles and stories on Business at LatestLY. Singapore, February 27: Takeda (TSE:4502/NYSE:TAK) today announced a strategic partnership with Biological E. Limited, a leading vaccines and biologics company in India, to manufacture Takeda's dengue vaccine, TAK-003. The partnership marks a crucial step in the fight against the global public health threat of dengue fever, aligning with the disease-specific target set by the World Health Organization (WHO) to achieve zero case-fatality rate due to dengue by 2030[i]. Business News | Takeda Accelerates Access to Its Dengue Vaccine Through 'Make in India' Manufacturing Partnership with Biological E..

Andhra pradeshUnited kingdomUnited statesDion warrenSouth east asiaDuddilla sridhar babuAnumula revanth reddyGary dubinLancet global healthWorld health organizationPharmceutical technologyMinistry of health malaysiaStrategic advisory group of expertsSoutheast asia organisationRegulatory agencyEuropean union